AbbVie Acquires Apogee Therapeutics for $10.9 Billion
AbbVie has agreed to acquire clinical-stage biotechnology company Apogee Therapeutics in an all-cash deal valued at approximately $10.9 billion, pending regulatory and shareholder approvals expected by Q3 2026. The acquisition targets Apogee's lead drug candidate zumilokibart for inflammatory conditions like eczema and asthma.
Topics: asthma atopic dermatitis biotechnology pharmaceuticals